Elevated [18F]FDOPA utilization in the periaqueductal gray and medial nucleus accumbens of patients with early Parkinson's disease

NeuroImage

Volumn 49, Issue 4, 2010, Pages 2933-2939

  Kumakura, Yoshitaka ^a,b   Danielsen, Erik H ^a,c   Gjedde, Albert ^a,c   Vernaleken, Ingo ^d   Buchholz, Hans Georg ^e   Heinz, Andreas ^f   Gründer, Gerhard ^d   Bartenstein, Peter ^g   Cumming, Paul ^g  

^a AARHUS UNIVERSITY   (Denmark)

^b UNIVERSITY OF TOKYO   (Japan)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d RWTH AACHEN UNIVERSITY   (Germany)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY OF MUNICH   (Germany)

Author keywords

FDOPA; Nucleus accumbens; Parkinson's disease; Periaqueductal gray

Indexed keywords

6 FLUORODOPA F 18; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CATECHOLAMINE NERVE CELL; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG TISSUE LEVEL; DRUG TRANSPORT; FEMALE; HUMAN; IMPULSE CONTROL DISORDER; LIMBIC SYSTEM; MALE; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PERIAQUEDUCTAL GRAY MATTER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SEROTONINERGIC NERVE CELL; STEADY STATE;

ADULT; AGED; DIHYDROXYPHENYLALANINE; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PERIAQUEDUCTAL GRAY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 73749084700     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2009.11.035     Document Type: Article

References (55)

1. Borek L.L., and Friedman J.H. Levodopa addiction in idiopathic Parkinson disease. Neurology 65 (2005) 1508
2. Borghammer P., Kumakura Y., and Cumming P. Fluorodopa F 18 positron emission tomography and the progression of Parkinson disease. Arch. Neurol. 62 (2005) 1480
3. Brown W.D., Taylor M.D., Roberts A.D., Oakes T.R., Schueller M.J., Holden J.E., Malischke L.M., DeJesus O.T., and Nickles R.J. FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa. Neurology 53 (1999) 1212-1218
4. Bruck A., Aalto S., Nurmi E., Bergman J., and Rinne J.O. Cortical 6-[18F]fluoro-l-dopa uptake and frontal cognitive functions in early Parkinson's disease. Neurobiol. Aging 26 (2005) 891-898
5. Carson R.E. PET parameter estimation using linear integration methods: bias and variability considerations. In: Uemura K., Lassen N.A., Jones T., and Kanno I. (Eds). Quantification of Brain Function: Tracer Kinetic and Image Analysis in Brain PET (1993), Excerpta Medica, New York, NY 499-507
6. Cumming P., and Gjedde A. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms. Synapse 29 (1998) 37-61
7. Cumming P., Leger G.C., Kuwabara H., and Gjedde A. Pharmacokinetics of plasma 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine ([18F]Fdopa) in humans. J. Cereb. Blood Flow Metab. 13 (1993) 668-675
8. Cumming P., Kuwabara H., and Gjedde A. A kinetic analysis of 6-[18F]fluoro-l-dihydroxyphenylalanine metabolism in the rat. J. Neurochem. 63 (1994) 1675-1682
9. Cumming P., Ljubic-Thibal V., Laliberte C., and Diksic M. The effect of unilateral neurotoxic lesions to serotonin fibres in the medial forebrain bundle on the metabolism of [3H]DOPA in the telencephalon of the living rat. Brain Res. 747 (1997) 60-69
10. Cumming P., Munk O.L., and Doudet D. Loss of metabolites from monkey striatum during PET with FDOPA. Synapse 41 (2001) 212-218
11. Doudet D.J., Rosa-Neto P., Munk O.L., Ruth T.J., Jivan S., and Cumming P. Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: a multi-tracer PET study. Neuroimage 30 (2006) 26-35
12. Flores J.A., Galan-Rodriguez B., Ramiro-Fuentes S., and Fernandez-Espejo E. Role for dopamine neurons of the rostral linear nucleus and periaqueductal gray in the rewarding and sensitizing properties of heroin. Neuropsychopharmacology 31 (2006) 1475-1488
13. Ghaemi M., Rudolf J., Hilker R., Herholz K., and Heiss W.D. Increased pineal Fdopa uptake is related to severity of Parkinson's disease-a PET study. J. Pineal. Res. 30 (2001) 213-219
14. Gillings N.M., Bender D., Falborg L., Marthi K., Munk O.L., and Cumming P. Kinetics of the metabolism of four PET radioligands in living minipigs. Nucl. Med. Biol. 28 (2001) 97-104
15. Gjedde A. Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: a re-examination. Brain Res. 257 (1982) 237-274
16. Gjedde A., Reith J., Dyve S., Leger G., Guttman M., Diksic M., Evans A., and Kuwabara H. Dopa decarboxylase activity of the living human brain. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 2721-2725
17. Grosset K.A., Macphee G., Pal G., Stewart D., Watt A., Davie J., and Grosset D.G. Problematic gambling on dopamine agonists: not such a rarity. Mov. Disord. 21 (2006) 2206-2208
18. Guttman M., Boileau I., Warsh J., Saint-Cyr J.A., Ginovart N., McCluskey T., Houle S., Wilson A., Mundo E., Rusjan P., Meyer J., and Kish S.J. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur. J. Neurol. 14 (2007) 523-528
19. Hilker R., Schweitzer K., Coburger S., Ghaemi M., Weisenbach S., Jacobs A.H., Rudolf J., Herholz K., and Heiss W.D. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch. Neurol. 62 (2005) 378-382
20. Holden J.E., Doudet D., Endres C.J., Chan G.L., Morrison K.S., Vingerhoets F.J., Snow B.J., Pate B.D., Sossi V., Buckley K.R., and Ruth T.J. Graphical analysis of 6-fluoro-l-dopa trapping: effect of inhibition of catechol-O-methyltransferase. J. Nucl. Med. 38 (1997) 1568-1574
21. Holthoff-Detto V.A., Kessler J., Herholz K., Bonner H., Pietrzyk U., Wurker M., Ghaemi M., Wienhard K., Wagner R., and Heiss W.D. Functional effects of striatal dysfunction in Parkinson disease. Arch. Neurol. 54 (1997) 145-150
22. Huang S.C., Yu D.C., Barrio J.R., Grafton S., Melega W.P., Hoffman J.M., Satyamurthy N., Mazziotta J.C., and Phelps M.E. Kinetics and modeling of L-6-[18F]fluoro-dopa in human positron emission tomographic studies. J. Cereb. Blood Flow Metab. 11 (1991) 898-913
23. Johnson P.L., Lightman S.L., and Lowry C.A. A functional subset of serotonergic neurons in the rat ventrolateral periaqueductal gray implicated in the inhibition of sympathoexcitation and panic. Ann. N. Y. Acad. Sci. 1018 (2004) 58-64
24. Kaasinen V., Nurmi E., Bruck A., Eskola O., Bergman J., Solin O., and Rinne J.O. Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. Brain 124 (2001) 1125-1130
25. Kaya A.H., Vlamings R., Tan S., Lim L.W., Magill P.J., Steinbusch H.W., Visser-Vandewalle V., Sharp T., and Temel Y. Increased electrical and metabolic activity in the dorsal raphe nucleus of Parkinsonian rats. Brain Res. 1221 (2008) 93-97
26. Koerts J., Leenders K.L., Koning M., Portman A.T., and van Beilen M. Striatal dopaminergic activity (FDOPA-PET) associated with cognitive items of a depression scale (MADRS) in Parkinson's disease. Eur. J. Neurosci. 25 (2007) 3132-3136
27. Kumakura Y., and Cumming P. PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches. Neuroscientist (2009) 2009. Sep., 29
28. Kumakura Y., Danielsen E.H., Reilhac A., Gjedde A., and Cumming P. Levodopa effect on [18F]fluorodopa influx to brain: normal volunteers and patients with Parkinson's disease. Acta Neurol. Scand. 110 (2004) 188-195
29. Kumakura Y., Vernaleken I., Grunder G., Bartenstein P., Gjedde A., and Cumming P. PET studies of net blood-brain clearance of FDOPA to human brain: age-dependent decline of [18F]fluorodopamine storage capacity. J. Cereb. Blood Flow Metab. 25 (2005) 807-819
30. Kumakura Y., Gjedde A., Danielsen E.H., Christensen S., and Cumming P. Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease: correlation with asymmetry of motor symptoms. J. Cereb. Blood Flow Metab. 26 (2006) 358-370
31. Kumakura Y., Cumming P., Vernaleken I., Buchholz H.G., Siessmeier T., Heinz A., Kienast T., Bartenstein P., and Grunder G. Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/positron emission tomography study. J. Neurosci. 27 (2007) 8080-8087
32. Kumakura Y., Vernaleken I., Buchholz H.G., Borghammer P., Danielsen E., Grunder G., Heinz A., Bartenstein P., and Cumming P. Age-dependent decline of steady state dopamine storage capacity of human brain: an FDOPA PET study. Neurobiol. Aging (2008) 2008. Jun., 7
33. Kuwabara H., Cumming P., Reith J., Leger G., Diksic M., Evans A.C., and Gjedde A. Human striatal l-dopa decarboxylase activity estimated in vivo using 6-[18F]fluoro-dopa and positron emission tomography: error analysis and application to normal subjects. J. Cereb. Blood Flow Metab. 13 (1993) 43-56
34. Martin W.R., Palmer M.R., Patlak C.S., and Calne D.B. Nigrostriatal function in humans studied with positron emission tomography. Ann. Neurol. 26 (1989) 535-542
35. Molina-Holgado E., Dewar K.M., Descarries L., and Reader T.A. Altered dopamine and serotonin metabolism in the dopamine-denervated and serotonin-hyperinnervated neostriatum of adult rat after neonatal 6-hydroxydopamine. J. Pharmacol. Exp. Ther. 270 (1994) 713-721
36. Moore R., Whone A., McGowan S., and Brooks D. Monoamine neuron innervation of the normal human brain: an 18F-DOPA PET study. Brain Res. 982 (2003) 137-145
37. Moore R.Y., Whone A.L., and Brooks D.J. Extrastriatal monoamine neuron function in Parkinson's disease: an 18F-dopa PET study. Neurobiol. Dis. 29 (2008) 381-390
38. Morrish P.K., Sawle G.V., and Brooks D.J. Clinical and [18F] dopa PET findings in early Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 59 (1995) 597-600
39. Patlak C.S., and Blasberg R.G. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J. Cereb. Blood Flow Metab. 5 (1985) 584-590
40. Patlak C.S., Blasberg R.G., and Fenstermacher J.D. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood. Flow. Metab. 3 (1983) 1-7
41. Pelosi G.G., and Correa F.M. Cardiovascular effects of noradrenaline microinjected into the dorsal periaqueductal gray area of unanaesthetized rats. Eur. J. Neurosci. 22 (2005) 3188-3194
42. Pobbe R.L., and Zangrossi H.J. 5-HT(1A) and 5-HT(2A) receptors in the rat dorsal periaqueductal gray mediate the antipanic-like effect induced by the stimulation of serotonergic neurons in the dorsal raphe nucleus. Psychopharmacology (Berl.) 183 (2005) 314-321
43. Potenza M.N., Voon V., and Weintraub D. Drug insight: impulse control disorders and dopamine therapies in Parkinson's disease. Nat. Clin. Pract. Neurol. 3 (2007) 664-672
44. Rakshi J.S., Uema T., Ito K., Bailey D.L., Morrish P.K., Ashburner J., Dagher A., Jenkins I.H., Friston K.J., and Brooks D.J. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study. Brain 122 (1999) 1637-1650
45. Reyes S., and Mitrofanis J. Patterns of FOS expression in the spinal cord and periaqueductal grey matter of 6OHDA-lesioned rats. Int. J. Neurosci. 118 (2008) 1053-1079
46. Rinne O.J., Nurmi E., Ruottinen H.M., Bergman J., Eskola O., and Solin O. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease. Synapse 40 (2001) 193-200
47. Sellings L.H., and Clarke P.B. Segregation of amphetamine reward and locomotor stimulation between nucleus accumbens medial shell and core. J. Neurosci. 23 (2003) 6295-6303
48. Siessmeier T., Kienast T., Wrase J., Larsen J.L., Braus D.F., Smolka M.N., Buchholz H.G., Schreckenberger M., Rosch F., Cumming P., Mann K., Bartenstein P., and Heinz A. Net influx of plasma 6-[18F]fluoro-l-DOPA (FDOPA) to the ventral striatum correlates with prefrontal processing of affective stimuli. Eur. J. Neurosci. 24 (2006) 305-313
49. Sossi V., Doudet D.J., and Holden J.E. A reversible tracer analysis approach to the study of effective dopamine turnover. J. Cereb. Blood Flow Metab. 21 (2001) 469-476
50. van Beilen M., Portman A.T., Kiers H.A., Maguire R.P., Kaasinen V., Koning M., Pruim J., and Leenders K.L. Striatal FDOPA uptake and cognition in advanced non-demented Parkinson's disease: a clinical and FDOPA-PET study. Parkinsonism Relat. Disord. 14 (2008) 224-228
51. Vernaleken I., Kumakura Y., Cumming P., Buchholz H.G., Siessmeier T., Stoeter P., Muller M.J., Bartenstein P., and Grunder G. Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge. Neuroimage 30 (2006) 1332-1339
52. Wang S., Zhang Q.J., Liu J., Wu Z.H., Wang T., Gui Z.H., Chen L., and Wang Y. Unilateral lesion of the nigrostriatal pathway induces an increase of neuronal firing of the midbrain raphe nuclei 5-HT neurons and a decrease of their response to 5-HT(1A) receptor stimulation in the rat. Neuroscience 159 (2009) 850-861
53. Whone A.L., Watts R.L., Stoessl A.J., Davis M., Reske S., Nahmias C., Lang A.E., Rascol O., Ribeiro M.J., Remy P., Poewe W.H., Hauser R.A., and Brooks D.J. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann. Neurol. 54 (2003) 93-101
54. Yamada H., Aimi Y., Nagatsu I., Taki K., Kudo M., and Arai R. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats. Neurosci. Res. 59 (2007) 1-7
55. Zhang Q.J., Gao R., Liu J., Liu Y.P., and Wang S. Changes in the firing activity of serotonergic neurons in the dorsal raphe nucleus in a rat model of Parkinson's disease. Sheng Li Xue Bao 59 (2007) 183-189